S. Lambrechts

Berardi, E., J van Driel, W., H.M Hermans, R., N Gaarenstroom, K., A.R Lok, C., Persijn-van Meerten, E. L. V., Nederend, J., Lambrechts, S., Lopez-Yurda, M., P Engbersen, M., J.V Rijsemus, C., M.J Lambregts, D., Laghi, A., G.J Aalbers, A., G.H Beets-Tan, R., F.M Kok, N., & J Lahaye, M. (2026). MRI in advanced ovarian cancer: multicentre MISSION trial. European Journal of Cancer, 238, Article 116614. https://doi.org/10.1016/j.ejca.2026.116614

Hildebrand, N. D., Sier, M. A. T., van Kuijk, S. M. J., Hoeijmakers, L. S. M., Ackermans, L. L. G. C., Ubachs, J., Stassen, L., Ruber, N. F. M., Schaghen-D'Antonio, V., Goedegebuure, E. P., Baade-Corpelijn, L., Bongers, B. C., Stoot, J., Sosef, M., Lambrechts, S., de Vos van Steenwijk, P. J., Engelen, M., Lubbers, T., Blokhuis, T. J., ... Rensen, S. S. M. (2025). Patient-recorded indexing measurements (PRIMS) - study protocol of a prospective observational cohort study to improve the accuracy of the diagnosis of cancer cachexia. BMC Cancer, 25(1), Article 1572. https://doi.org/10.1186/s12885-025-14979-z

Laven, P., Wenzel, H. H. B., van der Aa, M. A., Lambrechts, S., & Kruitwagen, R. F. P. M. (2025). Impact of lymph node dissection and adjuvant chemotherapy on survival of patients with early-stage ovarian cancer: Update of a national cohort study. Gynecologic Oncology, 200, 51-57. https://doi.org/10.1016/j.ygyno.2025.07.010

Zelisse, H. S., Snijders, M. L. H., Groenendijk, F. H., Halfwerk, J. B. G., Hooijer, G. K. J., van Driel, W. J., León-Castillo, A., Lok, C. A. R., Kooreman, L. F. S., Lambrechts, S., Roes, E.-M., Reinten, R. J., Heeling, M., Sandel, N. J., van Marion, R., Dijk, F., van de Vijver, M. J., Mom, C. H., & van Gent, M. D. J. M. (2025). The prognostic potential of molecular subtypes including estrogen receptor status in endometrioid ovarian cancer. Gynecologic Oncology, 196, 137-145. https://doi.org/10.1016/j.ygyno.2025.03.050

Zelisse, H. S., van Gent, M. D. J. M., Mom, C. H., de Ridder, S., Snijders, M. L. H., Heeling, M., Stoter, M., Broeks, A., Horlings, H. M., Lok, C. A. R., Bosch, S. L., Piek, J. M., Bart, J., Reyners, A. K. L., Wisman, G. B. A., Yigit, R., Boere, I. A., Collée, M., Groenendijk, F. H., ... Archipelago of Ovarian Cancer Research Consortium (2025). Evaluation of the recently established Dutch nationwide Archipelago of Ovarian Cancer Research biobank. Annals of diagnostic pathology, 74, Article 152411. https://doi.org/10.1016/j.anndiagpath.2024.152411

Hendrikse, C. S. E., Theelen, P. M. M., Verhaegh, W., Lambrechts, S., Bekkers, R. L. M., van de Stolpe, A., & Piek, J. M. J. (2024). Patient-Representative Cell Line Models in a Heterogeneous Disease: Comparison of Signaling Transduction Pathway Activity Between Ovarian Cancer Cell Lines and Ovarian Cancer. Cancers, 16(23), Article 4041. https://doi.org/10.3390/cancers16234041

van der Ploeg, P., Hendrikse, C. SE., Thijs, A. MJ., Westgeest, H. M., Smedts, H. PM., Vos, M. C., Jalving, M., Lok, C. AR., Boere, I. A., van Ham, M. APC., Ottevanger, P. B., Westermann, A. M., Mom, C. H., Lalisang, R. I., Lambrechts, S., Bekkers, R. LM., & Piek, J. MJ. (2024). Phenotype-guided targeted therapy based on functional signal transduction pathway activity in recurrent ovarian cancer patients: The STAPOVER study protocol. Heliyon, 10(1), Article e23170. https://doi.org/10.1016/j.heliyon.2023.e23170

Hendrikse, C. S. E., van der Ploeg, P., van de Kruis, N. M. A., Wilting, J. H. C., Oosterkamp, F., Theelen, P. M. M., Lok, C. A. R., de Hullu, J. A., Smedts, H. P. M., Vos, M. C., Pijlman, B. M., Kooreman, L. F. S., Bulten, J., Lentjes-Beer, M. H. F. M., Bosch, S. L., van de Stolpe, A., Lambrechts, S., Bekkers, R. L. M., & Piek, J. M. J. (2023). Functional estrogen receptor signal transduction pathway activity and antihormonal therapy response in low-grade ovarian carcinoma. Cancer, 129(9), 1361-1371. https://doi.org/10.1002/cncr.34661

Hendrikse, C. S. E., Theelen, P. M. M., van der Ploeg, P., Westgeest, H. M., Boere, I. A., Thijs, A. M. J., Ottevanger, P. B., van de Stolpe, A., Lambrechts, S., Bekkers, R. L. M., & Piek, J. M. J. (2023). The potential of RAS/RAF/MEK/ERK (MAPK) signaling pathway inhibitors in ovarian cancer: A systematic review and meta-analysis. Gynecologic Oncology, 171(1), 83-94. https://doi.org/10.1016/j.ygyno.2023.01.038